Global Urinary tract infection Market is the infection of the lower or upper urinary tract caused by bacterial agents such as Escherichia coli, Staphylococcus saprophyticus, and others. The symptoms associated with UTI are pain during urination, frequent urination and a feeling of urination despite having an empty bladder.
Global UTI treatment drugs market is valued at USD 8 billion in 2016, which is expected to reach to USD 9.89 billion in 2023 at a CAGR of 3.6 %.
Some of the dominant vendors operating in the report are Bayer AG, GlaxoSmithKline Novartis AG, Dr. Reddy’s Laboratories Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Cipla Inc., Johnson & Johnson, and others.
Almost 1 % of boys and 3 to 8 % of girls are diagnosed with UTI treatment. The annual cost of UTI treatment infections treatment is higher than $1 billion in the U.S. alone. The incidence rate of UTIs is 0.91 % of total population, and 2.05 % for a female population with E.coli being the most common pathogen accounting for 80 % to 90 % of all the cases.
Browse Complete 108 Pages Premium Research Report Enabled with 121 Respective Tables and Figures at https://www.marketresearchfuture.com/reports/urinary-tract-infection-market-6138
To generate a bird’s view of the global urinary tract infection market, the report is segmented based on drug class, clinical indications, end users, and regions.
- Based on drug class, the market is comprised of quinolones, aminoglycosides, β-lactam, azoles, and others.
- Based on clinical indications, this market is segmented into urethritis, cystitis, and pyelonephritis and others.
- Based on end users the market is segmented into hospitals, self-administered and others.
- Based on the regions, the market is segmented as North America, Europe, Asia Pacific Middle East and Africa and rest of the world.
North America led by the U.S. accounts for the maximum market share of the global UTI treatment market followed by Europe. The recent regulatory shift in the U.S. such as the implementation of Affordable Care Act and Hospital Readmissions Reduction Program coupled with Medicare initiative to penalize unnecessary patient readmissions is expected to charge the U.S UTI treatment market.
Europe has a higher hospitalization rate than the U.S. despite the U.S. having a substantial spending on healthcare. However, these markets are stagnant, and there is a definite shift towards the
Asia Pacific region led by India and China. The Asia Pacific will be the fastest growing market, and the growth will be driven by China, and India as these nations have huge population and the low cost of UTI treatment drug.
Get Sample Copy of Research Report@ https://www.marketresearchfuture.com/sample_request/6138
Some of the primary causes of UTI include unsafe intercourse, diabetes, and obesity, lack of hygiene. Due to the inherent complicated female anatomy, UTI infection affects females more than males. The World Health Organization (WHO) estimates that almost 50 % of the women suffer from UTI treatment at some point in time in their lives resulting in more than 1 million hospitalizations per year.
About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar, Pune
+1 646 845 9312